Surmodics to Present at Oppenheimer Healthcare Conference
Webcast is Live on Tuesday, March 21, at 10:55 a.m. (ET)
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Mar. 14, 2017--
Surmodics, Inc. (Nasdaq:SRDX), a leading provider of medical device and in
vitro diagnostic technologies to the healthcare industry, today
announced that Gary Maharaj, president and chief executive officer, and
Andy LaFrence, vice president of finance and information systems and
chief financial officer, will make a presentation to the investment
community at the Oppenheimer Healthcare Conference in New York City on
Tuesday, March 21, 2017, at 10:55 a.m. ET (9:55 a.m. CT).
A live audio webcast of the presentation, with accompanying slides, can
be accessed by going to the investor relations portion of the Company’s
website at www.surmodics.com
and clicking on the webcast icon. The webcast will be archived on the
Company’s website approximately three hours after the live event and
will be available for 90 days, through June 19, 2017.
About Surmodics, Inc.
Surmodics is the global leader in surface modification technologies for
intravascular medical devices and a leading provider of chemical
components for in vitro diagnostic (IVD) tests and microarrays.
Following two recent acquisitions of Creagh Medical and NorMedix, the
Company is executing a key growth strategy for its medical device
business by expanding to offer total intravascular product solutions to
its medical device customers. The combination of proprietary surface
technologies, along with enhanced device design, development and
manufacturing capabilities, enables Surmodics to significantly increase
the value it offers with highly differentiated intravascular solutions
designed and engineered to meet the most demanding requirements. With
this focus on offering total solutions, Surmodics’ mission remains to
improve the detection and treatment of disease. Surmodics is
headquartered in Eden Prairie, Minnesota. For more information about the
company, visit www.surmodics.com.
The content of Surmodics’ website is not part of this press release or
part of any filings that the company makes with the SEC.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170314005461/en/
Source: Surmodics, Inc.
Andy LaFrence, 952-500-7000